Compare DexCom, Inc. (DXCM) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $84.09 with minimal daily movement. Technical indicators show a bearish trend with strong selling pressure on moving averages, though oversold RSI levels suggest potential for a near-term bounce. The ETF continues its dividend distributions, with recent payments around $0.32-$0.34 per share. Fixed income ETFs are seeing renewed investor interest as markets reassess rate expectations amid economic uncertainty.

The outlook for TLT hinges on Federal Reserve policy direction and inflation trends. Current yields offer improved income compared to pre-2022 levels, but duration risk remains elevated. Key risks include unexpected Fed hawkishness and inflation persistence, while potential catalysts include economic slowdown prompting rate cuts. Wall Street sentiment is mixed as investors weigh yield attractiveness against interest rate volatility.